Indo US Bio-Tech Ltd

Indo US Bio-Tech Annual Report

Indo Us Bio-Tech Ltd submitted its Annual Report for FY 2025-2026. The 22nd Annual General Meeting is scheduled for September 30, 2026.

Indo US Bio-Tech Annual General Meeting

Indo Us Bio-Tech Limited has issued a notice for its 22nd Annual General Meeting, scheduled for September 30, 2026, to be conducted via video conferencing.

Indo US Bio-Tech Board Meeting Outcome

Indo Us Bio-Tech Ltd announced outcomes of its board meeting, including the date for its 22nd AGM and appointment of statutory auditors.

Indo US Bio-Tech Q1 FY27 Results: Net Profit ₹3 Cr, Down 36.2% YoY

Indo US Bio-Tech Ltd reported revenue from operations of ₹33 Cr (+7.1% YoY) and net profit of ₹3 Cr (-36.2% YoY) for Q1 FY27.

Key figure

Net profit ₹3 Cr · -36.2% YoY

Indo US Bio-Tech Annual General Meeting

Indo Us Bio-Tech Limited announced the postal ballot results. Shareholders approved the appointment of a new director and statutory auditor.

Indo US Bio-Tech Board Meeting Date

Indo Us Bio-Tech Ltd scheduled a board meeting for August 12, 2026. The board will consider unaudited financial results for the quarter ended June 30, 2026.

Indo US Bio-Tech Board Meeting Outcome

Indo Us Bio-Tech announced a revised effective date for board committee reconstitutions. The changes reflect director appointments and resignations effective from April 21, 2026.

Indo US Bio-Tech Management Change

Indo Us Bio-Tech Limited appointed Bhagat & Associates as Statutory Auditor following Gautam N Associates' resignation. The change aligns with administrative restructuring of audit assignments.

Indo US Bio-Tech Other Announcement

Indo Us Bio-Tech reconstituted its Audit, Nomination, and Stakeholders committees effective July 10, 2026. This follows the earlier appointment of Hemanshi Darsh Soni as Additional Director.

Indo US Bio-Tech Annual General Meeting

Indo Us Bio-Tech Ltd issued a Postal Ballot Notice for shareholder voting on director and auditor appointments. Voting via e-voting runs from July 5 to August 3, 2026.

Indo US Bio-Tech Board Meeting Outcome

Indo Us Bio-Tech Ltd's board decided to seek shareholder approval for a new independent director and statutory auditor via postal ballot. The process is scheduled for July-August 2026.

Indo US Bio-Tech Board Meeting Outcome

Board noted resignations and approved appointments of statutory and internal auditors. Changes are effective from June 15-16, 2026, subject to shareholder approval.

Indo US Bio-Tech Q4 FY26 Results: Net Profit ₹2 Cr, Down 45.9% YoY

Indo US Bio-Tech Ltd reported revenue from operations of ₹26 Cr (-22.2% YoY) and net profit of ₹2 Cr (-45.9% YoY) for Q4 FY26.

Key figure

Net profit ₹2 Cr · -45.9% YoY

Indo US Bio-Tech Financial Results

Indo Us Biotech Limited reported audited financial results for the year ended March 31, 2026. Revenue from operations reached ₹110.44 Crore, marking steady growth.

Indo US Bio-Tech Other Announcement

Indo Us Bio-Tech Limited filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report details governance compliance and historical regulatory observations.

Indo US Bio-Tech Board Meeting Date

Indo Us Bio-Tech scheduled a board meeting for May 29, 2026, to approve audited annual financial results. The trading window remains closed until May 30.

Indo US Bio-Tech Debt & Borrowing

Indo Us Bio-Tech Ltd has confirmed that it does not fall under the 'Large Corporate' category for the financial year. This disclosure follows SEBI's framework for fund raising via debt securities. Consequently, the company is not subject to the mandatory incremental borrowing requirements applicable to large corporate entities.

Indo US Bio-Tech Management Change

Indo Us Biotech Limited appointed Mrs. Hemanshi Darsh Soni as an Additional Independent Director for a five-year term effective April 21, 2026. Simultaneously, Mrs. Neha Sachinbhai Patel resigned from her position as Non-Executive Independent Director on the same date. These changes reflect a routine board reorganization.

Execution

60 months

Indo US Bio-Tech Management Change

Mrs. Nehaben Sachinbhai Patel has resigned from her position as a Non-Executive Independent Director at Indo Us Bio-Tech Limited effective April 21, 2026. She cited personal and unavoidable reasons for her departure and confirmed there are no other material reasons. She holds no other directorships in listed entities.

Indo US Bio-Tech Management Change

Indo Us Bio-Tech Limited has appointed Mrs. Hemanshi Darsh Soni as an Additional Non-Executive Independent Director for a five-year term effective April 21, 2026. This appointment, subject to shareholder approval, strengthens the company's board governance and independent oversight.

Execution

5 years

Indo US Bio-Tech Management Change

Mrs. Nehaben Sachinbhai Patel resigned as an Independent Director of Indo Us Bio-Tech Limited effective April 21, 2026, citing personal reasons. The Board accepted her resignation during their meeting on the same date. She confirmed there are no other material reasons for her departure.

Indo US Bio-Tech Management Change

Indo Us Bio-Tech Limited announced the resignation of Mrs. Nehaben Sachinbhai Patel from her position as Non-Executive and Independent Director, effective April 21, 2026. The director cited personal and unavoidable reasons for her departure, confirming there are no other material reasons for the resignation.

Indo US Bio-Tech Management Change

Indo Us Bio-Tech Limited has appointed Mrs. Hemanshi Darsh Soni as an Additional Director (Non-Executive Independent) for a five-year term effective April 21, 2026. The appointment is subject to shareholder approval at the next Annual General Meeting. Mrs. Soni is not related to any of the company's directors or key managerial personnel.

Execution

5 years

Indo US Bio-Tech Q3 FY26 Results: Net Profit ₹3 Cr, Down 41.2% YoY

Indo US Bio-Tech Ltd reported net profit of ₹3 Cr (-41.2% YoY) for Q3 FY26.

Key figure

Net profit ₹3 Cr · -41.2% YoY

Indo US Bio-Tech Other Announcement

Indo Us Bio-Tech Ltd submitted its compliance certificate under Regulation 74(5) for the quarter and year ended March 31, 2026. The registrar, Bigshare Services, confirmed that no securities were received for dematerialization during this period. This is a routine regulatory filing with no material impact on business operations.